GLAXOSMITHKLINE PLC Form 6-K January 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 13 January 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')				
	Name	Sir Andrew Witty			
	Position/status	Chief Executive Officer			
Ś	Initial notification/	T 1 1 1 1 1			
c)	amendment	Initial notification			
_	Details of the issuer, emission allowance	market participant, auction			
2.	platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
	LEI	5493000HZTVUYLO1D793			
0)	Details of the transaction(s): section to b				
3	instrument; (ii) each type of transaction;				
5.	place where transaction(s) has been cond				
	place where transaction(3) has been cone	Ordinary shares of 25 pence			
		each ('Ordinary Shares')			
a)	Description of the financial instrument	caeff (Ordinary Shares)			
		ISIN: GB0009252882			
		Acquisition of Ordinary			
		1 2			
		Shares following the re-investment of dividends			
b)	Nature of the transaction				
D)	Nature of the transaction	paid to shareholders on 12			
		January 2017, on shares held			
		through the Company's			
		ShareReward Plan.			
c)	Price(s) and volume(s)	Price(s) Volume(s)			
±15./338 43					
	n/a (single transaction)				
	Aggregated information				
d)	Aggregated information				
u)	Aggregated volume Price				
	riggiegated volume i nee				
e)	Date of the transaction	2017-01-12			
f)	Place of the transaction	London Stock Exchange			
f)		(XLON)			
1					
1.	Details of PDMR/person closely associat				
a)	Name	Ms E Walmsley			
b)	Position/status	CEO Designate			
c)	Initial notification/	Initial notification			
-)	amendment				
2.	Details of the issuer, emission allowance	e market participant, auction			
	platform, auctioneer or auction monitor				
-	Name	GlaxoSmithKline plc			
h)	LEI	5493000HZTVUYLO1D793			

- 5493000HZTVUYLO1D793
- 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

place where transaction(s) has been conducted

	place where transaction(s) has been conducted				
		Ordinary shares of 25 pence			
a)	Description of the financial instrument	each ('Ordinary Shares')			
u)	Description of the infanctur instrument				
		ISIN: GB0009252882			
		Acquisition of Ordinary			
		Shares following the			
		re-investment of dividends			
h)	Nature of the transaction	paid to shareholders on 12			
0)	Nature of the transaction	January 2017, on shares held			
		through the Company's			
		ShareReward Plan.			
c)	Price(s) and volume(s)	Price(s) Volume(s)			
•)		£15.7338 12			
	Aggregated information	n/a (single transaction)			
d)					
	Aggregated volume Price				
``		2017 01 12			
e)	Date of the transaction	2017-01-12			
f)	Place of the transaction	London Stock Exchange			
		(XLON)			
1.	Details of PDMR/person closely association	ted with them ('PCA')			
	Name	Mr R G Connor			
,		President, Global			
b)	Position/status	Manufacturing & Supply			
2)	Initial notification/				
c)	amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction				
۷.	platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
	Details of the transaction(s): section to b				
3.	instrument; (ii) each type of transaction;				
	place where transaction(s) has been cond				
		Ordinary shares of 25 pence			
a)	Description of the financial instrument	each ('Ordinary Shares')			
	•	ISINI CD0000252882			
		ISIN: GB0009252882 Acquisition of Ordinary			
		Shares following the re-investment of dividends			
h)	Nature of the transaction	paid to shareholders on 12			
U)		January 2017, on shares held			
		through the Company's			
		ShareReward Plan.			
		Sharence waru i idil.			
		Price(s) Volume(s)			
c)	Price(s) and volume(s)	Price(s) Volume(s) f15 7338 51			
c) d)	Price(s) and volume(s) Aggregated information	Price(s)Volume(s)£15.733851n/a (single transaction)			

Aggregated volume Price

e) f)	Date of the transaction Place of the transaction	2017-01-12 London Stock Exchange (XLON)	
 c) 2. a) b) 	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction;	Mr S Dingemans Chief Financial Officer Initial notification e market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 be repeated for (i) each type of (iii) each date; and (iv) each	
	place where transaction(s) has been conc	Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7338 16	
d) e) f)	Aggregated information Aggregated volume Price Date of the transaction Place of the transaction	n/a (single transaction) 2017-01-12 London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Mr N Hirons		
b)	Position/status	SVP, Global Ethics & Compliance		
c)	Initial notification/ amendment	Initial notification		

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Lugar i ning	J. GLAXOSIVITTIKLINE I LO - I		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction		
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
-)	Details of the transaction(s): section to b			
3				
5.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
	place where transaction(s) has been conc	Ordinary shares of 25 pence		
		each ('Ordinary Shares')		
a)	Description of the financial instrument	cach (Ordinary Shares)		
		ISIN: GB0009252882		
		Acquisition of Ordinary		
		Shares following the		
		re-investment of dividends		
b)	Nature of the transaction	paid to shareholders on 12		
, i		January 2017, on shares held		
		through the Company's		
		ShareReward Plan.		
c)	Price(s) and volume(s)	Price(s) Volume(s)		
		£15.7338 16		
		n/a (single transaction)		
	Aggregated information			
d)	Aggregated mormation			
u)	Aggregated volume Price			
	Aggregated volume Thee			
e)	Date of the transaction	2017-01-12		
,	Place of the transaction	London Stock Exchange		
f)		(XLON)		
1.	Details of PDMR/person closely associa	ted with them ('PCA')		
a)	Name	Mr S A Hussain		
1.)	De sitie a latatas	President, Global		
D)	Position/status	Pharmaceuticals		
~	Initial notification/	Initial notification		
c)	amendment	Initial notification		
n	Details of the issuer, emission allowance market participant, auction			
2.	platform, auctioneer or auction monitor			
a)) Name GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to b	e repeated for (i) each type of		

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 Ordinary shares of 25 pence

each ('Ordinary Shares')

- a) Description of the financial instrument
- b) Nature of the transaction

ISIN: GB0009252882

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.

a) $\mathbf{Prize}(s)$ and $\mathbf{volume}(s)$	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7338	11
	n/a (single tr	ansaction)

Aggregated information d)

Aggregated volume Price

e)	Date of the transaction	2017-01-12
f)	Place of the transaction	London Stock Exchange
		(XLON)

1.	Details of PDMR/	person closely	associated w	vith them	('PCA')
1.	Details of I Diving	person crosery	ubbooluted v	vitil them	(1011)

1.	Details of 1 Divid person closely associated with them (1 err)			
a)	Name	Mr D S Redfern		
b)	Position/status	Chief Strategy Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market partic	ipant, auction	
a)	Name	GlaxoSmithK	Lline plc	
b)	LEI	5493000HZT	VUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of			
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each			
	place where transaction(s) has been cond	lucted		
		Ordinary share	res of 25 pence	
		each ('Ordina	ry Shares')	
a)	Description of the financial instrument	ISIN: GB000	9252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017, on shares held through the Company's ShareReward Plan.		
c)	Price(s) and volume(s)	Price(s) £15.7338	Volume(s) 59	
d)	Aggregated information	n/a (single transaction)		

Aggregated volume Price

e) Date of the transaction

2017-01-12

- Place of the transaction
- f)